EBEdwin J. R. van Beek

Edwin J. R. van Beek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Edwin J. R. van Beek has a total of 949 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Noninvasive Thrombus Imaging in Patients With Ischemic Stroke

    by Beth Whittington, Craig Balmforth, Alessandro Giaj Levra, Laura Clark, Neil Craig, Audrey White, Krithika Loganath, Evangelos Tzolos, Allison Winarski, Rachael O. Forsythe, et al.

    BACKGROUND: Determining the source of thromboembolism in patients with acute ischemic stroke remains challenging because current diagnostic approaches rely largely on circumstantial and inferential associations rather than direct identification of the cause of stroke. Fluorine-18 GP1 ([ 18 F]GP1) is a novel radiotracer that binds with high affinity and specificity to activated glycoprotein IIb/IIIa receptors on activated platelets. We aimed to determine whether hybrid [ 18 F]GP1 positron emission tomography (PET) and computed tomography angiography could identify in vivo cardiovascular thromboembolism in patients with acute ischemic stroke and provide a mechanism-based assessment of stroke etiology. METHODS: In a single-center prospective observational cohort study, 100 patients presenting with acute ischemic stroke underwent hybrid [ 18 F]GP1 PET/computed tomography angiography within 21 days of symptom onset in addition to standard-of-care stroke investigations. Stroke etiology was classified using the causative classification system by an expert stroke physician blinded to [ 18 F]GP1 PET findings. In parallel, [ 18 F]GP1 PET/computed tomography angiography images were analyzed independently by readers who were blinded to all clinical data and causative classification system classification. We assessed whether [ 18 F]GP1 PET/computed tomography angiography could identify the source of in vivo cardiovascular thromboembolism, influence stroke classification, and predict recurrent cerebrovascular events. RESULTS: Cardiovascular [ 18 F]GP1 uptake indicative of thrombosis was identified in nearly two-thirds (n=63) of participants, changing stroke classification in over a quarter (n=26) of patients. In those with stroke of undetermined cause, the source of thrombus was identified in 18 of 41 (44%) participants, which included nonstenotic carotid atherothrombosis, native cardiac valve thrombosis, and paradoxical thromboembolism. During a median follow-up of 613 (interquartile interval, 251–788) days, recurrent stroke or transient ischemic attack occurred in 14 patients, 13 (93%) of whom had cardiovascular [ 18 F]GP1 uptake at baseline. Cardiovascular [ 18 F]GP1 uptake was associated with a 10.4-fold increased risk of recurrent events (95% CI, 1.35–79.40; P =0.024). CONCLUSIONS: Noninvasive thrombosis imaging is a novel technique that enables direct in vivo identification of thrombus formation and frequently reveals the source of thromboembolism in patients with acute ischemic stroke. This approach represents a shift from inference-based to mechanism-based stroke classification with potential implications for targeted prevention strategies and better patient outcomes. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT05636748.


  • Open Access

    Platelet activation and thrombosis in microvascular obstruction

    by Craig Balmforth, Alessandro Giaj Levra, Beth Whittington, Aidan Morgan, Mark G Macaskill, Evangelos Tzolos, Alex J Jordan, Tariq Ramtoola, Tim Clark, Michelle Rooney, et al.

    Aims: Microvascular obstruction (MVO) remains a major complication following coronary reperfusion, but its pathogenesis is poorly defined. We evaluated myocardial platelet activation and thrombosis using fluorine-18-labelled GP1 ([18F]GP1) positron emission tomography (PET) in patients with anterior ST-segment elevation myocardial infarction. Methods and results: In a single-centre observational cohort study, 100 patients with acute anterior ST-segment elevation myocardial infarction underwent hybrid cardiac [18F]GP1 PET and magnetic resonance (MR) imaging with gadolinium enhancement and repeat imaging at 3–6 months. Myocardial [18F]GP1 uptake was quantified using target-to-background ratio (TBRmax) and percentage myocardial uptake (burden) and compared with MR measures of infarction, MVO and adverse ventricular remodelling. One hundred patients (60 ± 10 years, 91% male) underwent [18F]GP1 PET/MR imaging at a median of 13 days following index presentation. Increased myocardial [18F]GP1 uptake was observed in 44% of participants (TBRmax 1.89 ± 0.50). All 40 patients with MR-defined MVO demonstrated myocardial [18F]GP1 uptake. Myocardial [18F]GP1 uptake burden correlated with (ρ = 0.84; P < 0.001), and exceeded (by 18%), MR-defined burden of MVO. Myocardial [18F]GP1 uptake was associated with infarct size, lower left ventricular ejection fraction and longer time-to-reperfusion. Angiographic no-reflow was the strongest independent association of MVO (adjusted odds ratio 16.15; P < 0.001). Persistent myocardial [18F]GP1 uptake at follow up (22%, 7/32) was associated with lower left ventricular ejection fraction. Resolution of cardiac MR-defined MVO was observed in 78% of patients at follow-up and was universally concordant with resolution of myocardial [18F]GP1 uptake. Conclusion: MVO following ST-segment elevation myocardial infarction is universally associated with myocardial platelet activation, extending beyond structural abnormalities identified by cardiac MR. These findings are consistent with an important mechanistic contribution of platelet-mediated microvascular thrombosis to no-reflow and MVO, highlighting a potentially targetable biological pathway in a condition for which effective therapies remain elusive.


  • Open Access

    PINPOINT: Integrating Computer Assisted Detection and Virtual Nodule Clinics for Early Lung Cancer Detection in Routine Practice, A Pilot Study

    by Asabi Leliveld, Bo Willems, Maurizio Balbi, Enrica Capelletto, Margarida Dias, Joyce Dits, Rosa Mirambeaux, Dylan Nuts, Jacob M. van Werkhoven, Silvia Novello, et al.

  • Open Access

    The crucial role of normative ageing in respiratory pathogenesis

    by Caroline M Weight, Amanda L Tatler, Robert T R Huckstepp, Ian M Adcock, Peter J Barnes, Edwin J R van Beek, Gary Christopher, Rachel L Clifford, Devesh J Dhasmana, Simon P Hart, et al.


  • Open Access

    MRI for Lung Cancer Management: Any Closer to Clinical Application?

    by Juergen Biederer, Liisa L. Bergmann, Jeanne B. Ackman, Bruno Hochhegger, Lea Azour, Simon M. F. Triphan, Julien Dinkel, Yoshiharu Ohno, Yoshiyuki Ozawa, Edwin J. R. van Beek, et al.

    Management of lung cancer (LC) encompasses screening, diagnosis, staging, radiotherapy planning and guidance, therapy monitoring and surveillance. Across these domains, magnetic resonance imaging (MRI) offers a range of morphological and functional imaging capabilities—including diffusion‐weighted imaging (DWI), dynamic contrast‐enhanced (DCE) imaging, and whole‐body MRI—to complement established imaging modalities. Recent technical advances have substantially improved the feasibility of lung MRI, enabling more reliable image acquisition and lesion assessment under controlled conditions. In LC screening, meta‐analyses and prospective studies indicate that MRI can detect solid pulmonary nodules above clinically actionable size thresholds with moderate to high sensitivity and a low false‐positive rate. However, the available evidence is largely derived from pilot studies, selected cohorts, and modeling‐based analyses. MRI should therefore be regarded as technically feasible for screening but not yet a validated alternative to low‐dose computed tomography in population‐based programs. For staging, whole‐body MRI incorporating DWI has demonstrated comparable diagnostic performance to standard multimodality pathways in prospective and randomized studies, with potential advantages including reduced radiation exposure and streamlined imaging workflows. In radiotherapy planning, DCE, DWI, and motion‐resolved MRI techniques can improve target delineation and treatment adaptation, but their use remains largely confined to specialized centers. MRI shows promise for therapy response assessment and prognostication through quantitative DCE‐ and DWI‐derived biomarkers, although reported parameters remain heterogeneous and insufficiently standardized for routine clinical decision‐making. Overall, MRI has established clinical utility in selected aspects of LC management, while broader adoption is currently limited by availability, standardization, and validation gaps. Further technical refinement and large‐scale prospective trials are required to define its role in routine clinical practice. Level of Evidence: 5. Technical Efficacy: Stage 2.


  • Functional Thoracic MRI: Recent Advances in Pulmonary Assessment

    by Juergen Biederer, Mark O. Wielpuetz, Grace Parraga, Yoshiharu Ohno, Mark Schiebler, James M. Wild, Jens Vogel-Claussen, Edwin J.R. van Beek, for the International Workshop for Pulmonary Functional Imaging (IWPFI), Mitchell Albert, et al.

    Functional thoracic MRI provides a comprehensive assessment of lung morphology and respiratory function, including ventilation, perfusion, airway pathophysiology, and respiratory mechanics, offering the potential to improve understanding of pulmonary physiology and inform clinical decision-making.


  • Functional Lung Imaging Using CT: An Update

    by Changhyun Lee, Juergen Biederer, Yoshiharu Ohno, Joon Beom Seo, Grace Parraga, David L. Levin, James C. Gee, Rohit Jena, Yoshiyuki Ozawa, Mark O. Wielpuetz, et al.

    Traditional morphologic CT imaging of the chest is increasingly being enhanced through innovative approaches, which enable the transformation toward comprehensive morphofunctional imaging and enhance our understanding of lung diseases and treatment interventions.